E
YMAB

Ergoteles’s Y-mAbs Therapeutics YMAB Stock Holding History

Ergoteles’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-191,869
Closed -$936K – 1814
2022
Q4 		$936K Buy
+191,869
New +$1.39M 0.03% 479
2022
Q3 		– Sell
-28,697
Closed -$434K – 2050
2022
Q2 		$434K Buy
28,697
+5,634
+24% +$65.7K 0.01% 903
2022
Q1 		$274K Buy
23,063
+4,497
+24% +$46.2K 0.01% 875
2021
Q4 		$301K Buy
+18,566
New +$397K 0.01% 851
2020
Q4 		– Sell
-5,224
Closed -$201K – 946
2020
Q3 		$201K Buy
+5,224
New +$208K 0.03% 483

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Ergoteles's YMAB Position: Q1 2023 in Review

Ergoteles sold out of Y-mAbs Therapeutics (YMAB) in Q1 2023, closing a stake of 191,869 shares — an estimated $936K sold.

Ergoteles first reported a position in YMAB in Q3 2020 and held it in 5 quarters. The position peaked at $936K in Q4 2022. 85 funds tracked by Wall St. Rank hold YMAB as of Q1 2023.

  • Ergoteles reported no remaining Y-mAbs Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 191,869 Y-mAbs Therapeutics shares in Q1 2023, an estimated $936K.
  • Ergoteles first reported a position in Y-mAbs Therapeutics in Q3 2020 and held it in 5 quarters.
  • Ergoteles's Y-mAbs Therapeutics position peaked at $936K in Q4 2022.
  • 85 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.